Brean Murray is cutting its price target to $37 from $42 on InterMune (ITMN -1%) to reflect a...
Brean Murray is cutting its price target to $37 from $42 on InterMune (ITMN -1%) to reflect a more conservative outlook than the guidance management provided. The firm cites the potential denial of European coverage for Esbriet and a subsequent delay in the commercialization.
From other sites
at CNBC.com (Sep 15, 2014)
at CNBC.com (Sep 11, 2014)
at MarketWatch.com (Sep 11, 2014)
at CNBC.com (Aug 28, 2014)
at CNBC.com (Aug 26, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs